Bioventus Inc. (BVS)

Bioventus Inc. (BVS) is a healthcare company (medical devices) based in the United States. The share price is $10.58, up 1.10% on the day, which values the company at $724.11M. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$10.58+1.10% today
Market value
$724.11M
P/E ratio
13.2×last 12 months
Forward P/E
11.9×
Funk Score
52/100
Against its own history
Well above its usual priceusual price $6.38
200-week average
$7.2546% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Bioventus Inc. in more detail

BVS trades at 13.2× its last twelve months' earnings, 11.9× next year's expected earnings, 1.2× sales. Measured against its own history, the price is 66% above what its usual multiples would imply ($6.38) — well above its usual price. It sits 46% above its 200-week average of $7.25.

Over the last five fiscal years Bioventus Inc. has compounded revenue 12.1% a year, free cash flow 5.5% a year. Its Funk Score is 52 out of 100 (financial strength 3.4, profitability 5.9, growth 5.2, value 6.1, each out of 10).

In its favour: Strong Piotroski score; Operating margin is expanding. Worth checking: Altman Z in the distress zone; Share count keeps rising.

1 of the superinvestors tracked here hold BVS, including Arnaud Ajdler (0.8% of the portfolio).

Superinvestors holding BVS

1 of the investors tracked here report a position in their latest 13F filing.

Bioventus Inc. (BVS): questions and answers

What is BVS's P/E ratio?

Bioventus Inc. trades at 13.2× its last twelve months' earnings and 11.9× next year's expected earnings.

What is BVS's PEG ratio?

Bioventus Inc.'s PEG ratio is 1.20 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Bioventus Inc.'s market cap?

Bioventus Inc. is valued at $724.11M at a share price of $10.58.

Is BVS overvalued or undervalued?

Against its own history, BVS is well above its usual price: the price is 66% above the $6.38 implied by the median multiples it has traded at (price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is BVS above its 200-week moving average?

Yes. BVS is 46.0% above its 200-week average of $7.25. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Bioventus Inc. growing?

Over the last five fiscal years Bioventus Inc.'s revenue grew 12.1% a year.

Cite this page

Funkfolio, “Bioventus Inc. (BVS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BVS

Underlying data: Yahoo Finance; company filings with the SEC.